Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 2/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298087 | 1.00 | HRH3 (0.50) | HRH3HTR2CPRKCAPRKCQPRKCD | |
| SCHEMBL4301609 | 1.00 | HRH3 (0.50) | HRH3HTR2CPRKCAPRKCQPRKCD | |
| SCHEMBL7881453 | 0.96 | HRH3 (0.49) | HRH3HTR2CPRKCAPRKCQPRKCD | |
| SCHEMBL4300155 | 0.91 | PRKCA (0.44) | HRH3HTR2CPRKCAPRKCQPRKCD | |
| SCHEMBL4300154 | 0.91 | PRKCA (0.44) | HRH3HTR2CPRKCAPRKCQPRKCD | |
| SCHEMBL4298258 | 0.90 | HCRTR1 (0.42) | HRH3PRKCAPRKCQPRKCDDGAT2 | |
| SCHEMBL4298265 | 0.90 | HCRTR1 (0.42) | HRH3PRKCAPRKCQPRKCDDGAT2 | |
| SCHEMBL4305001 | 0.90 | HCRTR1 (0.42) | HRH3PRKCAPRKCQPRKCDDGAT2 | |
| SCHEMBL4292670 | 0.87 | PRKCA (0.44) | HRH3PRKCAPRKCQPRKCDMLNR | |
| SCHEMBL4292664 | 0.87 | PRKCA (0.44) | HRH3PRKCAPRKCQPRKCDMLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | HTR6, HTR5A, TPH1 | HRH3 405/4885HTR2C 18/4885PRKCA 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.